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Quinoline is a heterocyclic aromatic organic compound having molec-
ular formula C9H7N, characterized by a double-ring structure that
contains a benzene ring fused to pyridine at two adjacent carbon
atoms. Quinoline is also known as, benzopyridine, benzo[b]pyridine,
1-benzazine and benzazine. It is a hygroscopic, yellowish oily liquid,
slightly soluble in water, soluble in alcohol, ether and many other
organic solvents. Isoquinoline is a congener of quinoline and differs
from quinoline in nitrogen position (at 2nd position) (Ferlin et al.,
2005).
Quinoline and isoquinoline alkaloids obtained from natural
sources show remarkable biological activities and relatively simple
structures have attracted great interest in the scientific community,
especially researchers involved in the chemistry of natural products.
Quinoline and its congeners have also attracted the interest of syn-
thetic organic chemists due to the need to obtain increased
amounts aimed at additional biological research. Quinoline alka-
loids derived from flowering plants, animals and microorganismsPlease cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009possessed numerous biological activity. Some source of the quino-
line or its derivatives and their biological activities are summarized
in Table 1.
Various quinoline derivatives have been synthesized and reported
for different activities. Quinoline derivatives are widely used as
‘‘parental” compounds to synthesize molecules with medical benefits,
especially with anti-malarial and anti-microbial activities. A number
of quinoline and its derivatives are known to possess antimicrobial,
antitumor, antifungal, hypotensive, anti HIV, analgesics and anti-
inflammatory activities. Quinoline and its analogues have recently been
examined for their modes of function in the inhibition of tyrosine
kinases, proteasome, tubulin polymerization, topoisomerase and
DNA repair. Substitution of the group in a suitable position of a
bioactive molecule is found to exert a profound pharmacological effect
(Gasparotto et al., 2006). The quinoline nucleus has naturally stirred in
many alkaloids with swaying antitumor activity, for example, camp-
tothecin (Wall et al., 1966). Srivastava et al. (2005) obtained a patent
for an isolation procedure of camptothecin a quinoline analogous from
Nothapodytes Foetida.velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
Table 1 Natural quinoline and its congener possess antitumor/anticancer activity.
Com.
No.
Reference Structure Quinoline
derivative/user
name
Source Use
1
Ortiz et al.
(2014)
Berberine Family of Berberidaceae Colon cancer
2
Wall et al.
(1966)
Camptothecin
Camptotheca acuminate,
Notihapodytes Foetida
Topoisomerase inhibitor
(anticancer agent)
3
Haseeb
et al. (2007)
Chelidonine Celandine
Lung and pancreatic
cancer
4
Haseeb
et al. (2007)
Chelerythrine Celandine
Lung and pancreatic
cancer
5
Abdel et al.
(2014)
Dictamine Dictaminus albus
Cytotoxicity to HepG2
cells
6
Cai et al.
(2010)
Lavendamycin Streptomyces levendulae Antitumor antibiotic
7
Djerassi
et al. (1958)
Lophocereine Lophocereus schotti Antitumor antibiotic
8
Tan et al.
(1991)
Nitidine Zanthoxylum nitidum
Topoisomerase inhibitor
(anticancer agent)
(continued on next page)
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Table 1 (continued)
Com.
No.
Reference Structure Quinoline
derivative/user
name
Source Use
9
Zhihu et al.
(2014)
Sanguinarine Sanguinaria
Lung and pancreatic
cancer
10
Rao et al.
(1963)
Streptonigrin Streptomyces flocculus Antitumor antibiotic
4 S. Jain et al.Applications of quinoline derivatives are fast spreading from anti-
cancer drugs to almost every branch of medicinal chemistry. Quinoline
derivatives represent a large number of antiproliferative agents exhibit-
ing cytotoxicity through DNA intercalation, causing interference in the
replication process (Ryckebusch et al., 2008). Actinomycin D, doxoru-
bicin, mitoxantrone and streptonigrin are quinoline analogues possess-
ing antibacterial or anti-cancer activity through DNA intercalation.
Most of these drugs are currently used in the treatment of human
malignancies target topoisomerase (types II) enzymes. Topoisomerase
inhibitors designated as ‘‘poisons” interact with DNA to form cleav-
able complexes, causing permanent DNA damage that triggers a series
of cellular events finally inducing apoptosis or other types of cell death.
Topoisomerases are nuclear enzymes that regulate topological and
conformational changes in DNA, critical to cellular processes such
as replication, transcription, chromosome segregation and mitosis.
There are two classes of DNA topoisomerase: (i) type I enzyme breaks
one DNA strand for the passage of a second strand, and (i) type II
enzyme breaks both strands of one DNA duplex for the passage of a
second DNA double strand. DNA topoisomerases (types II) are the
primary target for a number of quinoline derivatives, including
doxorubicin and mitoxantrone etc. Most of the anticancer drugs cur-
rently used in the treatment of human malignancies, as well as several
new series of drugs under development, are targeted at topoisomerase
II enzymes. Most of the quinoline based anticancer drugs currently
used in the treatment of human malignancies, as well as several new
series of drugs under development, are targeted at topoisomerase
enzymes (Schmidt et al., 2008).
Among the many possible strategies for improving the therapeutic
effectiveness of anticancer drugs, one of the most important is the syn-
thesis of new derivatives with modified structure. In the search for new
derivatives with advantageous biological properties many structural
modifications have already been attempted. Such modifications appear
to be a promising way for improvement of biological properties in
comparison with those of the parent anticancer compounds, because
such modifications exhibited lower toxicity and were found to be
highly cytotoxic to several neoplastic cell lines with multidrug
resistance.
In the present review, we have summarized our knowledge on
quinoline derivatives with respect to their anticancer activities, mecha-
nisms of action, structure-activity relationship (SAR), and selective
and specific activity against various cancer drug targets. In particular,
we focus our review on in vitro and in vivo anticancer activities of
quinoline derivatives in the context of cancer drug development and
refinement.Please cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.0092. Monosubstituted quinoline derivatives
2.1. 3-Quinoline derivatives
Several quinoline derivatives, isolated from natural sources or
prepared synthetically, are important for medicinal chemistry
and biomedical use. The quinoline derivatives that intercalate
DNA are of growing interest in the field of anticancer drugs.
A number of research programs directed toward developing
new approaches to a variety of heterocyclic ring systems for
anticancer activity, especially those containing 3-quinoline
derivatives have been widely reported.
Ghorab et al. (2015) reported a series of 3-quinoline deriva-
tives. Compounds were synthesized via reaction of 3-
aminoquinoline with ethyl cyanoacetate followed by reaction
with substituted aldehydes. The structures of the newly synthe-
sized compounds were confirmed by elemental analyses, and
spectroscopic techniques. All the newly synthesized com-
pounds were evaluated for their cytotoxic activity against a
human tumor breast cancer cell line (MCF7). It was found that
the compounds 2-Cyano-3-(4-hydroxy-3-methoxyphenyl)-
N-(quinolin-3-yl) acrylamide (11), 3-Oxo-N-(quinolin-3-yl)-
3H-benzol[f]chromene-2-carboxamide (12), 2-Cyano-3- (4-
fluorophenyl-N-(quinolin-3-yl) acrylamide (13) and 2-Cyano-
5-(4-(dimethylamino) phenyl)- N-(quinolin-3-yl) penta-2,4-
dienamide (14) exhibited higher activity with IC50 values of
29.8, 39.0, 40.0, 40.4 lmol L1, respectively. These compounds
showed remarkable cytotoxic activity compared to doxoru-
bicin as a positive control (Fig. 1).
2.2. 4-Quinoline derivatives
Reyes et al. (2010) synthesized a series of 4-quinoline substi-
tuted aminopyrimidine and 2-methylimidazo[1,2-a]pyridine
derivatives. The synthesized compounds were evaluated for
their cytotoxic activity against U251 (glioma), PC-3 (prostate),
K562 (leukemia), HCT-15 (colon), MCF7 (breast) and
SK-LU-1 (lung) cancer cell lines. Results showed that
quinolin-4-yl-substituted compound (15), persists cytotoxicvelopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 1 Structures of 3-quinoline derivatives (11–14) show cytotoxic activity against breast cancer cell line (MCF7).
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Figure 2 Structure of compound 4-(Quinolin-4-yl)-N-p-
tolylpyrimidin-2-amine (15), possessing cytotoxic and CDK
inhibitory activity.
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Review on developments of quinoline-based anticancer agents 5activity and is the most effective and selective against CDK1/
CycA than against CDK2/CycB, while quinolin-3-yl-
substituted compound is devoid of any cytotoxic activity
(Fig. 2). This result constituted a new lead of quinolin-4-yl-
substituted compounds for their cytotoxic and CDK inhibitory
activity from which more compelling and selective inhibitors
can be designed.2 R
16-17 18-21
IC50=49.01 - 77.67
Figure 3 Structure of compounds N-alkylated, 2-oxoquinoline
derivatives (16–21) shows good cytotoxic activity on the HEp-2
cell line (tumor of larynx).3. Disubstituted quinoline derivatives
3.1. N-alkylated, 2-oxoquinoline derivatives
N-alkylated quinoline derivatives exhibited a wide spectrum of
pharmacological activities, such as antiplasmodial, cytotoxic,
antibacterial, antiproliferative, antimalarial, and anticancer
activity. The incorporation of oxygen at second position inPlease cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009quinoline (i.e. 2-Oxoquinoline) may alter the biological
response of quinoline (Ryckebusch et al., 2003). Sagheer
et al. (2013) reported N-alkylated, 2-oxoquinoline derivatives
as cytotoxic agents. The quinoline was N-alkylated by the bro-
moacetic acid and then oxidized with an alkaline potassium
ferricyanide solution to get N-alkylated quinolone. Six new
quinoline derivatives (16–21) with high purity were synthesized
and tested for their cytotoxic activity on the HEp-2 cell line
(tumor of the larynx) with inhibitory concentration percent
of (IC%) range (Fig. 3). The results of cytotoxic studies
showed that all the synthesized compounds have IC50 (%)
value in the range of 49.01–77.67%. The result of cytotoxicity
confirms the anticancer activity of N-alkylated, 2-oxoquinoline
derivatives.velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Recently, photodynamic therapy is an emerging method of
non-invasive treatment of cancer in which drugs such as
Photofrin show localized toxicity on photoactivation at the
tumor cells leaving the healthy cells unaffected. There has been
increased interest in the discovery and investigation of com-
pounds that damage DNA upon irradiation, also known as
photonucleases, exhibited a large potential for therapeutic
applications chiefly in cancer disease (Armitage et al., 1998).
Importantly, the type and the efficiency of the photo cleavage
reaction will depend on the binding affinity and the binding
site that the photonuclease occupies. A number of 2,3-
disubstituted quinoline oxime derivatives have been reported
for their anticancer activity by means of DNA cleavage activ-
ity in cancerous cells.
Bindu et al. (2012) reported the simple, convenient and high
yielding synthesis of 2-chloro-3-formyl quinoline oxime esters
derivatives. The electrophoretic data showed concentration
and substitution dependent nucleolytic activities of 2-chloro-
3-formyl quinoline oxime esters. The DNA photo cleavage
studies were performed by neutral agarose gel electrophoresis
at different concentrations (40 lM and 80 lM) which indi-
cated that few of quinoline oxime esters (22–27) converted into
supercoiled pUC19 plasmid DNA to its nicked or linear form
(Fig. 4). The structure activity studies concluded that the elec-
tron donating groups are highly reactive radical and thus pos-
sessed remarkable anticancer activity, while the molecules
having halogen and nitro groups were less active. These elec-
trons donating groups abstracts hydrogen atoms efficiently
at C-40 of 2-deoxyribose in B-DNA.
In the continuous search of new 2,3-disubstituted quinoline
derivatives for anticancer activity, Broch et al. (2010) designed
and synthesized new quinoline derivatives. The synthesized
compounds were evaluated for their in vitro antiproliferative
activity toward a human fibroblast primary culture and two
human solid cancer cell lines (MCF-7 breast and PA 1, ovarian
carcinoma). Results showed that the dimeric analogous (2,20
Dimethoxy-3,70-biquinoline 28 and 2,20-Diethoxy-3,70-biquino
line 29) were slightly active toward PA1 and MCF-7 cell lines
with IC50 values in the range of 36–54 lM, and possessed bet-
ter cytotoxicity toward these two human solid cancer cell lines
as compared to trimeric compound (2,20,20’-triethoxy-3,70–30,
700-terquinoline 30). The trimeric analogue (30) showed mild
activity against the PA1 cell line with an IC50 value ofR
N Cl
N
O
O
22-27: p-ClC6H4; p-BrC6H4; p-NO2C6H4; p-FC6H4
o-FC6H4; m-dinitro-C6H3
Figure 4 Structure of compounds 2-chloro-3-formyl quinoline
oxime esters derivatives having good anticancer properties.
Please cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.00950 lM. The proposed reason for better activity of dimeric ana-
logues is due to its enhanced solubility over trimeric analogues,
and thus better cellular penetration (Fig. 5). The SAR studies
showed that the introduction of various substituents on the
heteroaromatic nucleus improved the solubility of compounds
and results better biological profile.
3.3. 2,4-Disubstituted quinoline derivatives
Quinoline ring having 2,4-disubstitution plays an important
role in the search of new anti-cancer agents as these derivatives
have shown excellent results through different mechanism of
action such as growth inhibitors by cell cycle arrest, apoptosis,
inhibition of angiogenesis, disruption of cell migration, and
modulation of nuclear receptor responsiveness (Lu et al.,
2008).
Kouznetsov et al. (2012) reported a series of 2,4-
disubstituted quinoline compounds, for their cytotoxic activ-
ity. The studies were further extended by the same research
group Ilango et al. (2015). Various 2,4-disubstituted quinolines
derivatives were synthesized from the reaction of aniline with
benzaldehyde and pyruvic acid to formed 2-phenylquinolin-
4-carboxylic acid, which converted to 2-phenylquinolin-4-
carbonyl chloride, and on the subsequent reaction with
substituted amines gave 2-phenylquinoline-4-substituted
phenylcarboxamide. The syntheses of compounds were
confirmed by spectroscopic techniques. The results of spec-
troscopy confirmed the synthesis of desired compounds with
adequate purity.
The newly synthesized compounds were screened for cyto-
toxic activity by Trypan blue dye exclusion technique using
Neubauer Hemocytometer. The Ara-c in a concentration of
10 lg/ml was used as standards. Among the synthesized com-
pounds, nine compounds showed % mortality above 50. How-
ever, three compounds were found to have a 70% mortality
when compared with Ara-c against the tumor cells. In spite
of cytotoxic activity, all the newly synthesized compounds also
showed good antibacterial and antifungal activities. Among
newly synthesized derivatives, compounds N-2-diphenyl
quinolin-4-carboxamide (31) and N-p-tolylquinolin-4-
carboxamide (32) were found to possess maximum cytotoxicity
(Fig. 6). The proposed reason for the superior cytotoxicity of
these two compounds was the presence of bulky aryl groups
at 2 and 4 positions which enhanced the activity of synthesized
quinoline derivatives. The research group also proposed that
the incorporation of the amido group in quinoline derivatives
enhanced their cytotoxic and antimicrobial activities, but the
presence of electron donating and electron withdrawing groups
on the two aryl rings did not make any significant difference in
their activity.
3.4. 3,5-Disubstituted quinoline derivatives
3,5-Disubstituted quinolines have been reported as potent c-
Jun N-terminal kinase (JNKs) inhibitors and lead to produced
anticancer activity. Three distinct genes encoding JNKs have
been identified (jnk1, jnk2, and jnk3). JNK3 has been shown
to mediate neuronal apoptosis and make inhibiting this iso-
form a promising therapeutic target for neurodegenerative dis-
eases such as Parkinson’s disease, Alzheimer’s disease, and
other CNS disorders. Currently JNK3 becomes primary targetvelopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 5 Structures of dimeric (28, 29) and trimeric (30) analogues of 2,3-disubstituted quinoline derivatives having improved
cytotoxicity against PA1/MCF-7 and PA1 cell line respectively.
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Figure 6 Structure of compounds N-2-diphenyl quinolin-4-carboxamide (31) and N-p-tolylquinolin-4-carboxamide (32) shows best
cytotoxicity among 2, 4-disubstituted quinoline compounds.
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et al., 2005; Kuan et al., 2003). Jiang et al. (2007) reported
the synthesis of a novel series as potent c-Jun N-terminal
kinase (JNK) inhibitors with selectivity against p38. The struc-
tures of 3,5-disubstituted quinolines were derived from 4-(2,7-
phenanthrolin-9-yl)phenol. The X-ray crystal structure of
inverse sulfonamide t-butyl analogue (33) in JNK3 revealed
an unexpected binding mode for this new scaffold with protein
and possessed a remarkable inhibition (0.15 lM IC50) against
JNK3 and devoid of inhibition against p38 (Fig. 7).Please cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.0093.5. 3,8-Disubstituted quinoline derivatives
Scolopendra subspinipes has been traditionally used for treating
febrile seizure, malignant tumor, neuralgia or diphtheria in ori-
ental countries. The inventors have extracted a novel quinoline
compound from scolopendra subspinipes termed as jineol, and
found that the extracted quinoline compound has cytotoxicity
to a cancerous cell. This quinoline alkaloid has an oxygen
atom at 3-carbon position and is rare in the nature. Nowadays
jineol a new 3-hydroxy quinolinic compound has been discov-velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 7 Structure of inverse sulfonamide t-butyl analogue (33)
showing unexpected JNK3 binding capability with remarkable
inhibitory activity (0.15 lM IC50) against p38 cell line.
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Figure 9 Structure of 3,8-dihydroxy-jineol derivatives (35)
shows remarkable cytotoxic activity using SRB assay.
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8 S. Jain et al.ered. It is known that the cyclic peptide structure of 3-hydroxy
quinoline has an anticancer activity and its derivative 3-
hydroxy quinoline-2-carboxylic acid, which can be obtained
from a microorganism also showed anticancer activity
(Matson et al., 1993). The amount of jineol (34) extracted from
scolopendra subspinipes is very limited for commercial use
(Fig. 8). Thus Cho et al. (2008), developed methods for synthe-
sis of jineol and its derivatives thereof which showed anti-
cancer activity. Jineol and its derivatives were synthesized by
the reduction of starting material 2-amino-3-methoxybenzoic
followed by acetylation then selective deacetylation. The reac-
tion was further proceed by the oxidation and Friedlander
condensation and hydrogenation yielded jineol 8-methyl ether
or jineol 3-benzyl ether.
The researchers patented a number of jineol derivatives
having structure at 3,8-dihydroxy-quinoline derivatives (35)
(Fig. 9). Jineol was extracted from scolopendra subspinipes with
an organic solvent, and purifying an anticancerous activating
portion by chromatography. Jineol showed cytotoxic activity
of the cells, such as A-549 non-small cell lung cancer,
SKOV-3 ovarian cancer, SK-Mel-2 melanoma, XP-498 central
nervous system cancer and HCT-15 colon cancer. This jineol
was utilized to derive its derivatives. The synthesized com-
pounds were characterized by spectroscopic techniques. The
cytotoxic activity of jineol derivatives was performed by SRB
assay against A-549, SKOV-3, SK-Mel-2, XP-498 and HCT-N
OH
H
H
H H
OH
H
34
Figure 8 Structure of jineol having anticancer activity.
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of jineol and its derivatives as compared to carboplatin, cis-
platin and adriamycin.
3.6. 4,7-Disubstituted quinolines derivatives
Bispo et al. (2015) reported a new and potent class of 7-chloro-
4-quinolinylhydrazone derivatives (36) as anticancer agents
(Fig. 10). The synthesized compounds were screened against
cancer cell lines using the MTT assay. The results of anticancer
activity showed that compounds exhibited good cytotoxic
activity against at least three cancer cell lines (SF-295, central
nervous system; HTC-8 colon and HL-60, leukemia), with IC50
values between 0.314 and 4.65 lg/cm3. Results showed that the
compounds having 2,6-dichloro hydrazone derivative were
more active as compared to monochlo, while di or trimethoxy
hydrazone derivatives were more active than monomethoxy.
Results also showed that 3rd position substituted hydrazone
showed best cytotoxic activity while N-methylation increased
biological activity of quinoline. However, 7-chloro substitution
on the quinoline ring decreased cytotoxic activity.
A plethora of the researcher’s findings suggests that
4-amino, 7-substituted-quinoline derivatives bear numerous
biological activities. These include anticancer, antioxidant,N
NH R
R
Cl
2
1
36
IC50=0.314-4.65
Figure 10 Structure of 7-chloro-4-quinolinylhydrazone deriva-
tives (36) shows improved cytotoxic activity using MTT assay.
velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Mcchesney et al. (1962) employed structure activity relation-
ship of 4-aminoquinoline derivatives for antimalarial activity.
Consideration has been given to the potential role of metabolic
transformations in the in vivo activation of 8-aminoquinoline.
Ghorab et al. (2014) designed and synthesized nineteen
compounds based on a 4-aminoquinoline scaffold. The synthe-
sized compounds bear N-substituted at the 4-position by aryl
or heteroaryl, quinolin- 3-yl, 2-methylquinolin-3-yl, thiazol-2-
yl, dapsone moieties and bis-compounds. The synthesized
compounds were assayed for in vitro using sulforhodamine B
stain (SRB) method of the antiproliferative activity against
the MCF-7 breast cancer cell line. Out of nineteen, seventeen
compounds showed moderate activity than the reference drug
doxorubicin, while compounds 7-(trifluoromethyl)-N-(3,4,5-tri
methoxyphenyl)quinolin-4-amine (37), N-(7-(trifluoromethyl)
quinolin-4-yl)quinolin-3-amine (38), 2-methyl-N-(7-trifluoro
methyl)quinolin-4-yl) quinolin-3-amine (39) and N-(4-(4-
aminophenylsulfonyl) phenyl)-7-chloroquinolin-4-amine (40)
were reported almost twice to thrice as potent as doxorubicin
(Fig. 11). The result of in vitro studies strongly recommended
that the 4-amino, 7-substituted-quinoline derivatives possess
antiproliferative activity.
Recently the combination of quinolines with chloroquine
has been reported as the most apoptosis-inducing agent used
against MCF-7 human breast cancer cells (Martirosyan
et al., 2004). All differentiation-inducing quinolines caused
growth suppression in MCF-7 and MCF10A cells by strong
suppression of E2F1 which results cell cycle arrest.NF3C
HN
NH3C
NF3C
NH
OCH3
H3CO
H3CO
Cl
37
39
Figure 11 Structure of 4-amino, 7-substituted-quinoline derivative
MCF-7 breast cancer cell line using sulforhodamine B stain (SRB) me
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(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009Ferrer et al. (2009) reported a series of new [(7-Chloroquino
lin-4-yl)amino]chalcone derivatives and were tested in vitro
antiproliferative activity against human prostate LNCaP
tumor cells. Compounds (2E)-3-(4-Chlorophenyl)-1-{3-[(7-chl
oroquinolin-4-yl)amino]phenyl}prop 2-en-1-one (4-chloro-30-
[(7-chloroquinolin-4-yl)amino]chalcone (41), (2E)-1-{3-[(7-Chl
oroquinolin-4-yl)amino]phenyl}-3-(3-fluorophenyl)prop-2-en-
1-one (30-[(7-chloroquinolin-4-yl)amino]-3-fluorochalcone (42)
and (2E)-1-{3-[(7-Chloroquinolin-4-yl)amino]phenyl}-3-phe
nylprop-2-en-1-one (30-[(7-chloroquinolin-4-yl)amino]chal
cone, (43) exhibited potential inhibitors of human prostate
cancer cell proliferation with IC50 values of 7.93 ± 2.05,
7.11 ± 2.06 and 6.95 ± 1.62 lg/mL respectively (Fig. 12).
Results showed that the presence of hydrogen or a halogen
on position 3rd or 4th in the aromatic ring improved the
antiproliferative activity of the reported compounds.
3.7. 6,8-Disubstituted quinoline derivatives
The quinoline and 6,8-disubstituted quinoline skeletons are
often used in the designs of many synthetic compounds with
diverse pharmacological properties. Okten et al. (2013)
described an easy route for synthesis of 6,8-disubstituted
quinoline derivatives since 6,8-dibromoquinolines. The reac-
tion starts with synthesis of 6,8-dibromoquinolines followed
by metal bromine exchange leading to produce various 6,8-
disubstituted quinoline derivatives. The synthesized com-
pounds were characterized by spectroscopic techniques. The
synthesized compounds were screened for antiproliferativeNF3C
HN
N
N
HN
S
O
O
NH2
38
40
s (37–40) showing improve antiproliferative activity against the
thod, with respect to doxorubicin.
velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 12 Structure of compounds [(7-Chloroquinolin-4-yl)amino]chalcone (41–43) exhibits potential antiproliferative activity against
prostate LNCaP tumor cells.
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Figure 13 Structure of compounds 6,8-dibromo-1,2,3,4-tetrahy-
droquinoline (44) and 6,8-dimethoxidequinoline (45) showing
comparable antiproliferative activity against HeLa/HT-29/C6
and HT-29 cancer cell lines respectively.
10 S. Jain et al.activity against several tumor cell lines. The results showed
that compound 6,8-dibromo-1,2,3,4-tetrahydroquinoline (44)
showed comparable antiproliferative activity against HeLa
(cervical epithelioid carcinoma cells), HT-29 (colon cells) and
C6 (brain tumor cells) in a concentration of 10 lg/mL,
30 lg/mL and 30 lg/mL respectively with respect to 5-FU.
Compound 6,8-dimethoxidequinoline (45) also showed
significant activity against HT-29 cells in the concentration
of 70 lg/mL with respect to 5-FU. The proposed reaction pro-
cedure avoids shortcoming of numerous conventional methods
(i.e. Skraup, Friedlander, Doebner-von Miller, Pfitzinger,
Conrad-Limpach, and Combes) including limited homogeny
and substitution on the quinoline ring system (Fig. 13).
4. Trisubstituted quinoline derivatives
4.1. 2,4,5-Trisubstituted quinoline derivatives
Enhancer of Zeste Homologue 2 (EZH2) is a member of the
histone-lysine N-methyltransferase (HKMT) family, which
methylates K9 and K27 of histone H3, leading to transcrip-
tional repression of the affected target genes. EZH2 has been
found to be over-activated or over-expressed in many cancer
types including colon, prostate, breast, and lung cancer
(Kleer et al., 2003). Recently EZH2 has become a choice of tar-Please cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009get for a number of researchers for the treatment of cancer.
EZH2 inhibitors had been discovered by many pharmaceutical
companies and academic institutes exposed in the treatment of
cancer. To date, a number of EZH2 inhibitors (Fig. 14) have
been reported (Nasveschuk et al., 2014; Bradley et al., 2014).
Unfortunately, the known EZH2 inhibitors have very limited
scaffold structures.
In the search of new potent EZH2 inhibitors Xiang et al.
(2015) discovered a new class of 5-methoxyquinoline deriva-
tives a congener of BIX-01294 (2-(hexahydro-4-methyl-1H-
1,4-diazepin-1-yl)-6,7-dimethoxy-N-[1-(phenylmethyl)- 4-piper
idinyl]-4-quinazolinamine, (Fig. 15). BIX-01294 is a well-
known histone methyltransferase G9a/GLP inhibitor contain-
ing a 1-benzylpiperidin-4-ylamino group (Kubicek et al.,
2007).
5-Methoxyquinoline derivatives were prepared by cycliza-
tion of 2-bromo-5-methoxyaniline and malonic acid, using
POCl3 as catalyst and solvent. The intermediate 8-bromo-2,4
-dichloro-5-methoxyquinoline was prepared which on subse-
quent reactions with n-BuLi in THF and CH3OH followed
on reaction with a variety of primary or secondary amines at
the 4-position of the quinoline moiety and finally on nucle-
ophilic substitution reaction with amines at the 2-position of
the quinoline moiety in i-PrOH under microwave conditions,
using TFA as an acid catalyst gave the desired series of com-
pounds. The quinoline derivatives were assayed for their anti-
cancer activity which was based on both enzymatic and
cellular assays, in which the enzymatic activities were deter-
mined by the AlphaLISA (EZH2) method, and the cell growth
inhibition potencies were evaluated on the HCT-15 (colon) and
MD-MBA-231 (breast) cell lines by the MTT method. The
results of these studies showed that compound 5-methoxy-2-(
4-methyl-1,4-diazepan-1-yl)-N-(1- methylpiperidin-4-yl)quino
lin-4-amine (46), displayed an IC50 value of 1.2 lM against
EZH2, decreased global H3K27me3 level in cells and also
showed good anti-viability activities against both HCT15
and MD-MBA-231 tumor cell lines (Fig. 16). Studies also indi-
cated that methoxy groups at the 5-position might be more
important for the potency of the compounds, and single or
double substitutions at other positions would not contribute
to the potency. Selectivity studies of compound (46) were also
done on different proteins, including SMYD3, G9a,velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 14 Structure of typical EZH2 inhibitors.
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Figure 15 Structure of compound 2-(hexahydro-4-methyl-1H-
1,4-diazepin-1-yl)-6,7-dimethoxy-N-[1-(phenylmethyl)- 4-piperidi-
nyl]-4-quinazolinamine (BIX-01294), a potent EZH2 inhibitors.
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(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009SUV39H1, SETDB1, PRMT1 and SETD8. Results of selectiv-
ity showed that the compound (46) is highly selective for
EZH2. Researchers concluded that the compound (46) could
be a lead compound deserving further structural optimization
due to the fact that it represents a new scaffold and possesses
low molecular weight.
4.2. 2,4,6-Trisubstituted quinolines
DNA alkylating agents have been widely used in chemother-
apy. Recently, the investigation of new alkylating agents for
cancer chemotherapy via the designing of DNA-directed alky-
lating agents or prodrug becomes a key area to overcome the
general drawbacks of alkylating agents. DNA-directed alkylat-
ing agents are generally synthesized by linking alkylating
pharmacophores (such as N-mustard residue) to DNA-affinic
molecules (such as DNA intercalating agents or DNA minor
groove binder) (Gourdie et al., 1990). These agents showedvelopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 16 Structure of compound 5-methoxy-2-(4-methyl-1,4-
diazepan-1-yl)-N-(1- methylpiperidin-4-yl)quinolin-4-amine (46)
showing good anti-viability activities against both HCT15 and
MD-MB-231 tumor cell lines.
12 S. Jain et al.higher cytotoxicity and better therapeutic efficacy than the cor-
responding untargeted alkylating agents. Studies on the struc-
ture–activity relationships of these conjugates suggest that the
selection of the DNA-affinic molecule (carrier), N-mustard
residue (alkyl or phenyl N-mustard) and the spacer (type and
length) greatly affect their antitumor activity. For example,
Tallimustine a proposed anticancer drug candidate for this
new class of cytotoxic compounds. It was evaluated in Phases
I and II clinical trials and expressed a promising anticancer
activity both in vivo and in vitro (Pezzoni et al., 1991).
Till date a number of DNA-directed alkylating agents, hav-
ing N-mustard residue have been reported. In the search of
new N-mustard alkylating agents Kakadiya et al. (2010)
reported a series of phenyl N-mustard quinoline conjugates
as potent DNA-directed alkylating agents. In his study quino-
lines were chosen as a DNA-affinic molecule, as they are DNA
minor groove binders. New N-mustard–quinoline conjugates
were synthesized, using urea or hydrazinecarboxamide as sta-N R
N
H
O
z
R
1
2
Z= NH or NH-NH
47: R1 = Me, R2 = H; 48: R1 = 3-
49: R1 = Me, R2 = 6,7-(OCH2O)
Figure 17 Structure of N-mustard–quinoline conjugates (47–50) sh
carcinoma MX-1 xenograft.
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(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009bilizing spacers. The new targets derivatives were subjected
to antitumor evaluation against a variety of human tumor cell
growth in vitro, therapeutic efficacy in vivo, and their capability
of DNA interstrand cross-linking. Results showed that com-
pounds having hydrazinecarboxamide as a linker showed
increased cytotoxic activity in comparison with the corre-
sponding compounds bearing a urea spacer. The therapeutic
efficacy against human tumor xenografts in animal model
study clearly exposed the complete tumor remission in nude
mice bearing human breast carcinoma MX-1 xenograft by
N-{4-[Bis(2-chloroethyl)amino]phenyl}-N0-(2-methyl-4-quino
linyl)urea (47); N-{4-[Bis(2-chloroethyl)amino]phenyl}-N0-[6-
methoxy- 2-(3-methoxy-phenyl) -4-quinolinyl]urea (48); N-{4-
[Bis(2-chloroethyl)amino]phenyl}-2-(6-methyl[1,3]- dioxolo[4,
5-g]quinolin-8-yl)-hydrazinecarboxamide (49) and N-{4-[Bis
(2-chloroethyl)amino]phenyl}-2-[6-(dimethylamino)- 2-methyl-
4-quinolinyl]-hydrazinecarboxamide (50). The study con-
cluded that the both linkers were able to lower the chemically
reactive N-mustard pharmacophore and thus the newly syn-
thesized conjugates possessed a long half-life in rat plasma
(Fig. 17).
4.3. 2,4,8-Trisubstituted quinoline derivatives
It is known that diverse polyfunctionalized quinoline mole-
cules are used as potential anticancer agents. As a part of a
medicinal chemistry program devoted to the search of new
anticancer compounds, 2,4,8-trisubstituted quinoline deriva-
tives could serve as models for the development of new antitu-
mor drugs. It was reported that chemical modulation at the C-
2 position of quinoline would alter the biological activity of the
new quinoline compounds. The introduction of a hetaryl moi-
ety in the C-2 position of the quinoline ring would possibly
enhance the lipophilicity and DNA-quinoline binding proper-
ties of the prepared compounds and thus may augment the
anticancer activity. Kouznetsov et al. (2012) accounted C-2
quinoline derivatives that possessed good cytotoxic activity.
They identified structural similarities between sixteen C-2-
substituted quinolines compounds and reported structures as
anticancer. The synthesized compounds were tested in specific
human cancer cell lines (MCF-7, H-460 and SF-268) and
against nonspecific Vero cell lines and THP-1 monocyteN(CH2CH2Cl)2
MeO-C6H4, R2 = 6-MeO
; 50: R1 = Me, R2 = 6-NMe2
owing improvement of anticancer activity against human breast
velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 18 Structures of compounds 6-Methoxy-2-(thiophen-2-yl)quinoline (51); 8-Ethyl-4-methyl-2-(pyridin-4-yl)quinoline (52) and 8-
Propyl-4-methyl-2-(pyridin-4-yl)quinoline (53) show excellent cytotoxicity against the specific human cancer cell lines (MCF-7, H-460 and
SF-268).
Review on developments of quinoline-based anticancer agents 13macrophages, which indicated that 2-a-furyl- and 2-c-pyridinyl
quinoline derivatives 6-Methoxy-2-(thiophen-2-yl)quinoline
(51); 8-Ethyl-4-methyl-2-(pyridin-4-yl)quinoline (52) and 8-Pro
pyl-4-methyl-2-(pyridin-4-yl)quinoline (53) are active against
the three specific cancer cell lines (MCF-7, H-460 and SF-
268) and, at the same time, were devoid of cytotoxic effect
on nonspecific Vero cell lines and THP-1 monocyte macro-
phages when compared to adriamycin and camptothecin as
standard drugs (Fig. 18). Biological activity and SAR results
were compared with different molecular descriptors deter-
mined in silico using online available software, in an attempt
to show a relationship with the possible mode of action of
these quinoline derivatives.
4.4. 2-Substituted-4-amino-6-halogenquinoline derivatives
Gefitinib and pelitinib the 4-aminoquinazoline and
4-aminoquinoline skeletons respectively, are considered to be
the promising nucleus for antitumor drug development. As a
result, a great number of novel 4-aminoquinazoline and
4-aminoquinoline derivatives have been developed in succes-
sion. Two series of novel 2-substituted-4-amino-6-halogenqui
nolines were designed, synthesized and evaluated by Jiang
et al. (2012) for their antiproliferative activity against H-460
(lung), HT-29 (colon), HepG2 (liver) and SGC-7901 (stomach)
cancer cell lines in vitro. The pharmacological results indicated
that most compounds with 2-arylvinyl substituents exhibitedN
Cl
HN
N
CH3
CH3
OCH354
IC50=0.03, 0.55, 0.33, 1.24
Figure 19 Structure of compound (E)-N1-(6-Chloro-2-(4-meth-
oxystyryl)quinolin-4-yl)-N2,N2-dimethylethane-1,2-diamine (54)
shows improve antiproliferative activity over H-460, HT-29,
HepG2 and SGC-7901 cancer cell lines.
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(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009good to excellent antiproliferative activity. Among them,
the compound (E)-N1-(6-Chloro-2-(4-methoxystyryl)quinolin-
4-yl)-N2,N2-dimethylethane-1,2-diamine (54) (with a 4-
methoxystyryl group at the C-2 position and a dimethy-
laminoalkylamino substituent at the C-4 position) was
considered promising lead for further structural modifications
with IC50 values of 0.03 lM, 0.55 lM, 0.33 lM and 1.24 lM,
against H-460, HT-29, HepG2 and SGC-7901 cancer cell lines
respectively which was 2.5- to 186-fold more active than gefi-
tinib (Fig. 19). The prelude SARs showed that the improved
activity depended strongly on the introduction of an ethylene
linkage between the nucleus and aryl moiety.
4.5. 2,8-Bis(trifluoromethyl)-4-substituted quinoline derivatives
Meshram et al. (2012) synthesized various 2,8-bis(trifluorome
thyl)-4-substituted quinoline derivatives since 4-substituted
iodoquinoline on reaction with boronic acids in the presence
of a palladium catalyst under basic conditions or by the use
of Triton B as a base. Synthesized compounds were character-
ized by spectroscopic techniques. Cell proliferation or viability
of the synthesized compounds were assayed via MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrasolium bromide] assay
against the HL-60 (myeloid leukemia) and U937 (leukemia
monocyte lymphoma) cell lines using etoposide as a reference
drug. Results of cytotoxicity studies showed that synthesized
quinoline derivatives were toxic to human HL-60 and U937
cell lines in the concentration of 100–200 lg/ml. Compound
(55) [4-(3,5-dimethyl-1H-pyrazol-4-yl)-2,8-bis (trifluo-
romethyl) quinoline] was found to be a most potent antiprolif-
erative agent (Fig. 20). This compound possessed IC50 value
19.88 ± 3.35 lg/ml and 43.95 ± 3.53 lg/ml in HL-60 and
U937 cell lines respectively.
4.6. 4-Anilino-8-hydroxy-2-phenylquinoline derivatives
Chen et al. (2006) reported the synthesis and antiproliferative
evaluation of certain 4-anilino-8-methoxy-2-phenylquinoline
and 4-anilino-8-hydroxy-2-phenylquinoline derivatives. The
results showed that the antiproliferative activity of 40-COMe-
substituted derivatives decreased in an order of 6-OMe
(3.89 lM) > 8-OMe (10.47 lM) > 8-OH (14.45 lM), signify-
ing that the position of substitution at the quinoline ring was
crucial. For 30-COMe derivatives, the antiproliferative activity
of 8-OH (4-(3-Acetylanilino)-8-hydroxy-2-phenylquinoline)
(56, 1.20 lM) was found to be more potent than its 8-OMe
counterpart (8.91 lM), indicating that a H-bond donating sub-velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 20 Structure of compound 4-(3,5-dimethyl-1H-pyrazol-4-
yl)-2,8-bis (trifluoromethyl) quinoline (55) shows highest anti-
cancer activity against HL-60 and U937 cell lines.
14 S. Jain et al.stituent was more favorable than that of a H-bonding accept-
ing group. Similarly, for 8-OH derivatives, the antiproliferative
effect of -COMe (56) was more potent than its oxime deriva-
tive (2.88 lM), which in turn was more potent than the methy-
loxime counterpart (5.50 lM) (Fig. 21). In continuation, the
studies showed that the compound (56) was principally active
against the growth of certain solid cancer cells, such as HCT-
116 (colon cancer), MCF7 and MDA-MB-435 (breast cancer)
with GI50 values of 0.07, <0.01 and <0.01 lM, respectively.
4.7. 8-Hydroxy-2-methyl-7- substituted quinoline derivatives
Nowadays, researchers are focusing on biologically active
quinoline analogues and fluorescent compounds capable of
staining cancer cells. Researchers are trying to increase the
lipophilicity of quinoline derivatives to enhance the permeabil-
ity of the derivatives through the cell membranes, while their
antiproliferative activities render them interesting as leading
structures for anticancer agents or (in case of non-active com-IC50=0.07, <0.01, <0.01
N
HN
CH3
O
OH
21
Figure 21 Structure of compound 4-(3-Acetylanilino)-8-
hydroxy-2-phenylquinoline (56) shows significant antiproliferative
activity against HCT-116, MCF7 and MDA-MB-435 cancer cell
lines.
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(2014) reported a series of 8-hydroxy-2-methyl-quinolone
derivatives with benzylamide substitution and characterized
by spectroscopic techniques. Compounds were investigated
for fluorescent properties. Compounds 8-Hydroxy-2-methyl
quinoline-7-carboxylic acid (3- phenylbutyl)-amide (57) and 8
-Hydroxy-2-methylquinoline-7-carboxylic acid phenethy-
lamide (58) showed highest fluorescence, while remaining com-
pounds also possessed remarkable fluorescence. The results of
fluorescence studied showed that compounds having an unsub-
stituted aryl system or substituted ACH3 or AF showed the
best fluorescence intensity while substitution with AOCH3 or
AOH in the aryl ring decreased fluorescence. Synthesized com-
pounds were also utilized for biological assays and were tested
by the MTS assay against the wild type of human colon ade-
nocarcinoma cell line (HCT116) and mutants with disabled
TP53 gene (HCT116 p53). The synthesized compounds were
also screened for their cytotoxicity against murine melanoma
cell line (B16-F10) and normal human dermal fibroblasts.
The compound 2-Hydroxybenzoic acid N’-(8-hydroxy-2-meth
ylquinoline-7-carbonyl)-hydrazide (59) was found to possess
highest cytotoxic activity and was active in inhibiting the pro-
liferation of all tumor cell lines and possessed highest cytotoxic
activity but very poor fluorescence, too weak for observations
(Fig. 22).
4.8. Thiosemicarbazones based on quinoline scaffold
Thiosemicarbazones exhibit potent anticancer activity through
the blocking of ribonucleotide reductase or by specific redox
activity. Serda et al. (2010) showed that reduction of complex
of Fe3+-thiosemicarbazone lead to generation of reactive oxy-
gen species (ROS) which may also be responsible for inhibition
of ribonucleotide reductase as they are able to quench the tyro-
syl radical of the R2 subunit of ribonucleotide reductase.
Quinoline and its derivatives were also reported as a potent
antiproliferative scaffold. Number of thiosemicarbazones
based on quinoline compounds has been synthesized using
microwave assisted techniques.
Microwave assisted chemistry carried most of the steps in
efficient manner and green technique and also provide good
(above 80%) yields of the main product. The proposed tech-R1
R2
NH
O
N
OH
CH3
57: R1=(CH2)4, R2=H; 58: R1=(CH2)2, R2=H
59: R1=NH-CO, R2=OH
Figure 22 Structure of 8-hydroxy-2-methyl-quinolone deriva-
tives (57–59) possesses highest cytotoxicity against B16-F10,
NHDF cell lines but with very poor fluorescence.
velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 23 Structure of thiosemicarbazones based quinoline compounds (60, 61) shows good antiproliferative activity against the
HCT116 cell line by MTT assay.
Review on developments of quinoline-based anticancer agents 15nique is time and cost efficient and allows obtaining a rela-
tively wide group of compounds for biological tests. Structures
of all new compounds were confirmed with spectroscopic tech-
niques. The antiproliferative activity of thiosemicarbazones
based quinoline compounds (60 and 61) was assessed by the
MTT assay against the HCT116 (human colon carcinoma) cell
line (Fig. 23). Tested compounds exhibited improved antipro-
liferative activities against HCT116 cancer cells.
5. Tetrasubstituted quinoline derivatives
5.1. 2,3-Disubstituted-6,7-dimethoxy (dihydroxy) quinoline
derivatives
RAF (rapidly-growing fibrosarcoma) kinases are serine/thre-
onine kinases, and they are part of the mitogen activated pro-
tein kinase signal transduction cascade. This cascade is vital
for numerous cellular fates, including cell growth, differentia-
tion, proliferation and survival (Weber et al., 2000). Imatinib
a diarylamides derivative was used in the treatment of gas-
trointestinal stromal tumors, thyroid cancer, breast cancer,
meningioma, ovarian cancer, and nonsmall cell lung cancer
in combination with other drugs (Wellbrock et al., 2004).
Gamal et al. (2014) synthesized a new series of diarylamide
derivatives possessing dimethoxy(dihydroxy)quinoline
nucleus. The synthesized compounds were tested for in vitro
antiproliferative activities over NCI-58 cancer cell line panel
of nine different cancer types. Compounds 3,4-dichloro-N-(4-
(6,7-dimethoxy-2- methylquinolin-3-yloxy)phenyl)benzamide
(62); N-(4-(6,7-dimethoxy-2-methylquinolin-3-yloxy)phenyl)-2
,3- dihydrobenzo[b][1,4]dioxine-5-carboxamide (63); 3-(Tri
fluoromethyl)-N-(4-(6,7-dimethoxy-2-methylquinolin-3-yloxy)
phenyl)benzamide (64); 4-Chloro-3-(trifluoromethyl)-N-(4-(6,
7-dimethoxy-2- methylquinolin-3-yloxy)phenyl)benzamide
(65); N-(4-(6,7-dimethoxy-2-methylquinolin-3-yloxy)phenyl)-3
,5- bis(trifluoromethyl)benzamide (66) showed the most
promising results among all the synthesized compounds at aPlease cite this article in press as: Jain, S. et al., Comprehensive review on current de
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These compounds (62–66) were further tested in 5-dose testing
mode in order to determine their IC50 values, and the results
were compared with those of imatinib and gefitinib which
showed that the five compounds were more potent than ima-
tinib against all the cell lines of nine different cancer types
(Table 2). Compound 66 showed the highest inhibited activity
and was further tested against C-RAF kinase inhibition.
Results of C-RAF kinase inhibition showed 76.65% inhibition
at 10 mM. So it can be concluded that C-RAF kinase inhibi-
tion is a possible mechanism of the antiproliferative activity
of this compound. The structure activity relationship (SAR)
studies of synthesized compounds indicated that 6,7-
dimethoxyquinoline scaffold was more favorable for activity
than 6,7-dihydroxyquinoline. The O linker was optimal for
the activity too. Taken together, they can give information
about the pharmacophore of this series of compounds.
5.2. 6,7-Substituted-5,8-quinolinequinone derivatives
5,8-Quinolinequinones derivatives reported to possess a wide
spectrum of biological properties that include anti-tumor,
anti-inflammatory and anti-bacterial activities (Cheng et al.,
2008; Castellano et al., 2008). Streptonigrin, isolated from
the bacterium Streptomyces flocculus showed antitumor activ-
ity, having 5,8-quinolinequinones nub, which was one of the
first compounds to be systematically modified in an attempt
to correlate specific structural features with anti-cancer proper-
ties (Fig. 24) (Rao et al., 1963). Earlier structure–activity stud-
ies (SARs) concluded that the 7-aminoquinolinequinone-
moiety of streptonigrin was crucial for anti-tumor activity;
however, further studies showed that the addition of
electron-withdrawing groups at the 6- and/or 7-positions of
the quinolinequinone results enhanced rates of DNA degrada-
tion (Rao et al., 1974; Lown et al., 1976; Shaikh et al., 1986).
Unfortunately, the high toxicity of streptonigrin has limited its
therapeutic value (Davis et al., 1978; Bolza´n et al., 2001).velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
Table 2 Structures of the 2,3-disubstituted-6,7-dimethoxy (dihydroxy) quinoline derivatives (60–64) with their IC50 values (lM) over
the most sensitive cell line of each subpanel.
Com. No. R X Ar Cancer cell lines
RPMI-
8226a
HOP-
92b
HCT-
116c
SF-
295d
SK-MEL-5e OVCAR-4f A498g PC-3h BT-549i
62 CH3 O 3.70 16.10 4.26 1.59 4.99 5.26 20.60 4.77 3.91
63 CH3 O 2.98 3.93 3.42 2.91 2.92 3.32 2.06 2.49 1.71
64 CH3 O 3.67 3.08 3.22 2.73 2.45 3.68 1.78 2.85 3.31
65 CH3 O 5.43 13.60 4.18 2.28 10.60 5.58 2.42 4.30 8.86
66 CH3 O 1.57 1.82 1.56 1.64 2b.76 4.53 1.13 1.66 3.02
Imatinib 6.31 12.59 12.59 19.95 12.59 19.95 19.95 19.95 15.85
Gefitinib 6.31 0.32 3.16 10.00 3.16 6.31 0.63 5.01 3.16
a Leukemia cell line.
b Non-small cell lung cancer cell line.
c Colon cancer cell line.
d CNS cancer cell line.
e Melanoma cell line.
f Ovarian cancer cell line.
g Renal cancer cell line.
h Prostate cancer cell line.
i Breast cancer cell line.
16 S. Jain et al.Mulchin et al. (2010) reported a series of 6,7-substituted
5,8-quinolinequinones derivatives and identified their anti-
cancer, anti-inflammatory or tuberculostatic activity. The
starting material of synthesis was 8-hydroxyquinoline or 8-
hydroxy-2-methyl-quinoline, which on the subsequent reaction
with sodium chlorate gave oxidative product dichloro-
quinones. These dichloro-quinones were then treated with a
variety of amine nucleophiles to give the 6 and/or 7-
substituted 5,8-quinolinequinolines products in good (65–
96%) yield. The anti-cancer activity of the synthesized com-
pounds was measured against HL60 cells (IC50) and human
T-cells (IC50) from healthy volunteers using the MTT assay.
These quinolinequinones showed promise as anti-cancer activ-
ity. Results showed that the introduction of a sulfur group at
the 7-position of the quinolinequinone (6-methylamino-7-met
hylsulfanyl-5,8-quinolinequinone (67) and 6-amino-7- methyl
sulfonyl-5,8-quinolinequinone (68)) led to the discovery of aPlease cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009number of biologically active compounds that exhibited selec-
tivity for leukemic cells over T-cells, a highly desirable prop-
erty for an anti-cancer drug, while a di-chloro or di-thiol-
substituted quinolinequinone gave better anti-inflammatory
activity (Fig. 25).
6. Heterocyclic fused quinoline derivatives
6.1. 1,2-Quinoline-platinum complex
The compound belonging to a series of platinum(II) complexes
bearing piperidine (pip) as a ligand, exhibited notable antitu-
mor activity (Da et al., 2001; Solin et al., 1982). Thanh et al.
(2014) reported a [PtCl2(pip)(quinoline)] complex, in which
the quinoline ligand is replaced by an N,O-bidentate quinal-
date ligand and quinoline-piperidine ligands are arranged in
cis positions. The researchers also reported a new chloridovelopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Streptonigrin
Figure 24 Structure of streptonigrin, having antitumor activity,
with 5,8-quinolinequinones nub.
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compound (69) in which the quinoline ring of the quinaldate
ligand occupies a transposition with respect to the piperidine
ring (Fig. 26). The compound was synthesized in two steps.
In a first step the quinaldic acid in its ionic form coordinates
with PtII via the O atom of the carboxylate group first and
in a cis position with respect to piperidine based on the trans
effect, while in a second step, the quinaldic acid coordinates
with PtII also via its N atom, resulting in the cyclic complex.
The cytotoxic activity of the synthesized compound (69)
was tested and recorded for four human cancer cells of
HepG2, RD, MCF7 and Fl. The IC50 values of the reported
compound were found to be 4.46, 2.59, >10 and 5.60 lg ml1
respectively.
6.2. Pyrroloquinolines derivatives
Lee et al. (2004) identified a novel series of substituted
pyrroloquinolines that selectively inhibited the function of
P-glycoprotein (Pgp) without modulating multidrug
resistance-related protein 1 (MRP 1). The synthesized com-
pounds were screened for their toxicity toward drug-sensitive
tumor cells (i.e. MCF-7, T24) and for their ability to antago-
nize Pgp mediated drug-resistant cells (i.e. NCI/ADR) andN
O
O H
N
CH3
S
CH3
67
Figure 25 Structure of 6,7-substituted 5,8-quinolinequinones derivati
and human T-cells.
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showed that the dihydropyrroloquinolines inhibited Pgp to
varying degrees, without any significant inhibition of MRP
1. The compound Pgp-4008 (70) was found to be most potent
in inhibition of Pgp in vitro (Fig. 27).
6.3. Indolo[2,3-b]quinoline derivatives
5,11-Dimethyl-5H-indolo[2,3-b]quinoline (DiMIQ, 71), the
synthetic analogue of indolo[2,3-b]quinoline, reported high
cytotoxic activity and inhibits the proliferation of mouth carci-
noma KB cells (at a concentration of 1 mM) (Czoch
et al.,1994) (Fig. 28). Moreover, its activity is similar to the
cytotoxic activity of doxorubicin (0.8 mM against KB cells) a
marketed anticancer drug (Kaczmarek et al., 1999). Unfortu-
nately, DiMIQ (71) has limited practical applicability in the
treatment of cancer, possibly due to its high toxicity, lack of
selectivity and very low solubility in aqueous solutions, espe-
cially at neutral pH. The high toxicity and low bioavailability
of DiMIQ (71), prompted researchers to look for new ana-
logues which would conform to the high requirements neces-
sary for anticancer drugs: potent and selective activity and
low side effects.
In the search of new DiMIQ congeners, Sidoryk et al.
(2015) reported new indolo[2,3-b]quinoline derivatives con-
taining guanidine, amino acid or guanylamino acid sub-
stituents. Results revealed that the attachment of the
guanidine, or guanylamino acid chain directly to the DiMIQ
or 6H-indolo[2,3-b]quinoline moiety significantly perked up
its selective cytotoxicity against almost all cancer cell lines,
while decreasing this activity against the normal cell line. Com-
pounds N-guanyl-N-(5,11-dimethyl-5H-indolo[2,3-b]quinolin-
9-yl)- amine dihydrochloride (72) and N-guanyl-N-[6-(2-dime
thylaminoethyl)-11-methyl-6Hindolo[ 2,3-b]quinolin-9-yl]-
amine tetrahydrochloride (73) showed highest in vitro cytotox-
icity and possessed selectivity between normal and cancer cell
lines (Fig. 29). The cytotoxicity of compound (72) was found
to be about 600-fold lower against normal fibroblasts than
against A549 and MCF-7 cancer cell lines. The mechanism
of action of synthesized compounds was also studied for
guanidine derivatives, which showed that compounds (72
and 73) were very effective inducers of apoptosis. The results
of mechanism of action studies proved that the compounds
(72 and 73) produced antiproliferative activity through DNA
interactions probably lead to the inhibition of DNA synthesis
and consequent arrest the cells in S cell cycle phase. Com-N
O
O H
N
CH3
S
CH3
O O
68
ves (67, 68) shows significant anticancer activity against HL60 cells
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IC50=4.46, 2.59, >10, 5.60
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Figure 26 Structure of compound chlorido(piperidine-jN)-
(quinoline-2-carboxylato-j2N,O)platinum(II) (69), shows signifi-
cant cytotoxicity against human cancer cells of HepG2, RD,
MCF7 and Fl.
N N
HN C2H5
O
PGP-4008(70)
Figure 27 Structure of compound Pgp-4008 (70), most potent in
inhibition of Pgp in vitro.
NN
CH3
CH3
DiMIQ (71)
Figure 28 Structure of compound 5,11-dimethyl-5H-indolo[2,3-
b]quinoline (DiMIQ, 71), a indolo derivative shows high cytotoxic
activity and inhibits the proliferation of mouth carcinoma KB
cells.
18 S. Jain et al.pound (72), interacted more strongly with DNA than that of
compound (73), and was also more efficient in the induction
of apoptosis. The studies concluded that the conjugates con-
taining the guanidine group directly linked to the core struc-
ture confirmed highly potent and selective anticancer activity.Please cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.0096.4. Anilinofuro[2,3-b]quinoline derivatives
Chen et al. (2005) synthesized 4-anilinofuro[2,3-b]quinoline
and angular 4-anilinofuro[3,2-c]quinoline derivatives and eval-
uated in vitro against the full panel of NCI’s 60 cancer cell
lines. Compound 1-(4-(furo[2,3-b]quinolin-4-ylamino)phenyl)
ethanone (74) was found to be the most cytotoxic with a mean
GI50 value of 0.025 lM (Fig. 30). The results showed that sub-
stitution at either furo[2,3-b]quinoline ring (2a, 2b, and 5b) or
4-anilino moiety (3–7) decreased cytotoxicity.
6.5. Indolo-, pyrrolo-, benzofuro and 6-anilinoindolo quinoline
derivative
Chen et al. (2002) synthesized certain indolo-, pyrrolo-, and
benzofuro-quinolin-2(1H)-ones and 6-anilinoindoloquinoline
derivatives and evaluated in vitro against a three-cell line panel
consisting of MCF7 (Breast), NCI-H460 (Lung), and SF-268
(CNS). The results have shown that cytotoxicity decreased in
the order of 6-anilinoindoloquinolines > indoloquinolin-2(1H)-
ones > pyrroloquinolin-2(1H)-ones > benzofuroquinolin-2(1H)-
ones. Among them, 1-(3-(11H-indolo(3,2-c)quinolin-6ylamino)ph
enyl) ethanoneoximehydrochloride (75) and its 2-chloroderivative
(76) were most active, with a mean GI50 values of 1.70 and
1.35 mM, respectively (Fig. 31).Both compounds (75,76)were also
found to inhibit the growth of SNB-75 (CNS cancer cell) with a
GI50 value of less than 0.01 mM.
Atwell et al. (1972) synthesized acridine derivatives having
an amino group at position 9 of acridine, and found that some
of them had the effect of inhibiting leukemia. Cain et al. (1974)
reported the interrelation between the anticancer effect of the
acridine derivatives and the specific kind of alkylamino group
at position 9 of acridine, and found that the most effective
derivative is N-(4-(9-acridinylamino)-3-methoxyphenyl)-metha
nesulfonamide (amsacrine). Yamato et al. (1988) obtained a
patent for compounds having indenoquinoline, benzofuro-
quinoline or benzothienoquinoline in lieu of the acridine skele-
tal structure of amsacrine, the process for the preparation
thereof. In the present structure X was O, S or CH2 (77)
(Fig. 32). These compounds showed intensive antiproliferative
activity. The antiproliferative activity was determined by mea-
suring the 50% growth inhibition (ED50) of KB-cells. The
numbers of surviving cells were counted by a Kohlter’s coun-
ter, and the counted number was compared to that of the con-
trol to find the concentration of the drug for inhibiting the
growth by 50%, thus found concentration being estimated as
the ED50 value. In vivo activity showed the prolonging life of
P-388 murine leukemia cell line with cancer and these synthe-
sized compounds were found to be devoid of any acute
toxicity.
6.6. Indeno [1,2-c]quinoline derivatives
Although the quinoline ring is found in a wide variety of bio-
logically active compounds and is frequently condensed with
various heterocycles leads to produce remarkable active multi-
faceted. Synthesis and biological evaluation of the indeno [1,2-
c] quinoline skeleton attracts limited attention. NSC 314622
(78) an indenoquinoline analogue, was first identified as a
novel Topoisomerase I inhibitor with better pharmacokinetic
features than camptothecin (Fig. 33) (Antony et al., 2003).velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
N N
CH3
CH3
HN
NH
NH2
N N
CH3
HN
NH
NH2
N
CH3
CH3
72 73
Figure 29 Structure of indolo[2,3-b]quinoline derivatives (72, 73) shows remarkable cytotoxicity against A549 and MCF-7 cancer cell
lines.
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Figure 30 Structure of compound 1-(4-(furo[2,3-b]quinolin-4-
ylamino)phenyl) ethanone (74) shows most cytotoxicity against
NCI’s 60 cancer cell lines.
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cially indeno [1,2-c]isoquinoline derivatives have been synthe-
sized and proved to possess DNA Top I inhibitory activity.
These compounds bind to a transient Top I DNA covalent
complex and inhibited the resealing of a single-strand nick thatN
N
H
NH
CH3
N
OH
75
GI50=1.70
Figure 31 Structure of compounds 1-(3-(11H-indolo(3,2-c)quinolin
chloro derivative (76) shows cytotoxicity against MCF7, NCI-H460, S
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DNA (Hsiang et al., 1985; Hertzberg et al., 1989).
In the search of new, potent indeno[1,2-c]quinoline deriva-
tives, Tseng et al. (2008) synthesized some new indeno[1,2-c]
quinoline derivatives and reported their antiproliferative eval-
uation against the growth of six cancer cell lines including
human cervical epithelioid carcinoma (HeLa), oral squamous
cell carcinoma (SAS), hepatocellular carcinoma (SKHep),
human stomach adenocarcinoma (AGS), prostate cancer
(PC-3), and non-small cell lung cancer (A549). All indeno
[1,2-c]quinoline derivatives were derived from isatin. The
antiproliferative activity was measured by determining the
concentration of substances that inhibited the growth of
50% of cells (GI50). The results illustrated that the compound
9-Methoxy-6-(piperazin-1-yl)-11H-indeno[1,2-c]- quinolin-11-
one O-3-aminopropyl oxime (79) was the most potent with
GI50 values of 0.52, 0.74, 6.76, and 0.64 lM against the
growth of HeLa, SKHep, AGS, and A549 cells, respectively.
The study also showed that the potency of synthesized com-
pounds was decreased in an order of aminoalkoxy-
imino > hydroxyimino > alkoxyimino > carbonyl. Flowcy-
tometric analysis indicated that the compound 9-Methoxy-6-
(piperazin-1-yl)-11H-indeno[1,2-c]- quinolin-11-one O-3-
(dimethylamino)propyl oxime (80) can induce cell cycle arrestN
N
H
NH
CH3
N
OH
Cl76
GI50=1.35
-6ylamino)phenyl) ethanone oxime hydrochloride (75) and its 2-
NB-75 and SF-268 cancer cell lines.
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Figure 32 Structure of compounds indenoquinoline, benzofuro-
quinoline or benzothienoquinoline derivatives (77) showing inten-
sive antiproliferative activity against KB-cancer cells and
prolonging the life of P-388 murine leukemia cell line with cancer.
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Figure 33 Structure of indenoquinoline analogue (NSC 314622,
78) shows Topoisomerase I inhibitory activity.
20 S. Jain et al.in S phase, and DNA polyploidy (>4n) followed by apoptosis
(Fig. 34).
6.7. 6,8-Diarylthieno[3,2-c]quinoline-2-carboxylate scaffold
The 6,8-diarylthieno[3,2-c]quinoline-based compounds con-
tinue to attract a great deal of attention in the research because
of their rich biological activities including antibacterialN
OCH3
NO
N
NH
H2N
79
GI50=0.52, 0.74, 6.76, 0.64
Figure 34 Structure of indeno[1,2-c]quinoline derivatives (79–80) s
AGS, and A549 cancerous cells.
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anti-inflammatory agents (Cesare et al., 1999). Recently a
number of thieno[3,2-c]quinoline derivatives were found to
inhibit protein kinases in cancer cells (Beydoun et al., 2012;
Pierre et al., 2011). Avetisyan et al. (2007) reported a series
of substituted 2,4-dimethyl-thieno[3,2-c]quinolones deriva-
tives, which were prepared via intramolecular cyclization and
subsequent aromatization of 3-(2-chloroprop-2-en-1-yl)- and
3-(2-oxopropyl)-2-methylquinolin-4-thiols. Mphahlele et al.
(2014) produced [(6,8-diarylthieno[3,2-c]quinoline)]-2-carboxy
lates derivatives via direct one-pot base-promoted conjugate
addition–elimination of 6,8-dibromo-4-chloroquinoline-3-car
baldehyde with methyl mercaptoacetate and subsequent
cyclization afforded methyl [(6,8-dibromothieno[3,2-c]quino
line)]-2-carboxylate followed by Suzuki-Miyaura cross-
coupling with arylboronic acids to yield desired compounds.
These synthesized compounds were screened for their cytotox-
icity against the human breast cancer cell line MCF-7 using the
MTT assay. Cytotoxicity of the synthesized compounds was
also evaluated by measuring cell kinetics using the xCELLi-
gence Real Time Cell Analysis (RTCA) system. Compounds
Methyl [(6,8-Dibromothieno[3,2-c]quinoline)]-2-carboxylate
(81); Methyl 6,8-bis(4-methoxyphenyl)thieno[3,2-c]quinoline-
2-carboxylate (82) and Ethyl 6,8-bis(4-methoxyphenyl)thieno
[3,2-c]quinoline-2-carboxylate (83) showed remarkable cyto-
toxic activity against human breast adenocarcinoma cell line
(MCF-7 cells) either by using MTT assay or in Real Time Cell
Analysis (Fig. 35). The compounds inhibited cancer cell
growth in a dose- and time-dependent manner and their
LC50 values, were accountable to compare to nocodazole, a
well-established cytotoxic drug. The structure-activity relation-
ship analysis suggested that the cytotoxicity of the synthesized
compounds seems to be dependent on the electronic effects and
lipophilicity of the substituent on the para position of the 6-
and 8-phenyl rings. The structure-activity relationship analysis
provided a guideline for the readers to design new derivatives
with increased activity.
6.8. Thieno (2,3)-quinolone derivatives
Koruznjak et al. (2002) reported the novel synthesis scheme of
thieno (39,29:4,5)thieno(2,3)-quinolone derivatives and per-
formed their cytostatic activities against malignant cell lines:N
OCH3
NO
N
NH
N
H3C
H3C
80
hows significant antiproliferative activity against HeLa, SKHep,
velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 35 Structure of [(6,8-diarylthieno[3,2-c]quinoline)]-2-carboxylates derivatives (81–83) showing remarkable cytotoxicity against
MCF-7 cell line either by using MTT assay or in Real Time Cell Analysis.
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Figure 36 Structure of compounds thieno (39,29:4,5)thieno(2,3)-quinolone derivatives (84 and 85). Compound (84) shows best
anticancer activity while compound (85) shows least anticancer activity against MiaPaCa2, MCF7, HeLa, Hep2, CaCo-2, HBL and WI-38
cell lines.
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Figure 37 Structure of compound 3-(9-acridinylamino)-5-
(hydroxymethyl)aniline (AHMA, 86), capable of inhibiting the
growth of certain solid tumors.
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laryngeal (Hep2), colon (CaCo-2), melanoma (HBL), and
human fibroblast cell lines (WI-38). All tested compounds
exhibited strong inhibitory activities against all cell lines tested.
The results showed that the compound (84), which bears the 3-
dimethylaminopropyl substituent on quinolone nitrogen and
methoxycarbonyl substituent on position 9, exhibited marked
antitumor activity. On the contrary, compound (85), which
also bears the 3-dimethylaminopropyl substituent on the qui-
nolone nitrogen, but anilido substituent on position 9, exhib-
ited less antitumor activity than the others (Fig. 36).
6.9. 6H-indolo [2,3-b]quinoline derivatives
9-Anilinoacridine derivatives have been extensively studied as
potential chemotherapeutic agents due to their capability of
intercalating DNA, leading to the inhibition of topoisomerase
II. Su et al. (1995) stated that further structural modification
lead to the discovery of an improved broad spectrum antitu-
mor agent, 3-(9-acridinylamino)-5-(hydroxymethyl)aniline
(AHMA, 86), is capable of inhibiting the growth of certain
solid tumors such as mammary adenocarcinoma, melanoma
and lung carcinoma in mice (Fig. 37).
These results promoted to synthesize and evaluate
4-anilinofuro[2,3-b]quinoline derivatives, which were struc-
turally related to 9-Anilinoacridine derivatives.Please cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009Chen et al. (2004) synthesized and reported the anticancer
evaluation of certain 11-substituted 6H-indolo[2,3-b]
quinolines and their methylated derivatives. These 6H-indolo
[2,3-b]quinoline derivatives were prepared from the commer-
cially available 1,4-dihydroxyquinoline through alkylation,
chlorination, nucleophilic reaction, and ring cyclization. The
in vitro anticancer assay indicated that 5-methylated deriva-
tives were more cytotoxic than their respective 6-methylatedvelopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 38 Structure of compound 11-(4-methoxyanilino)-6-
methyl-6H-indolo[2,3- b]quinoline (87) shows selective cytotoxic-
ities for HL-60 (TB), K-562, MOLT-4, RPMI-8226 and SR cancer
cells.
22 S. Jain et al.counterparts. Among them, 11-(4-methoxyanilino)-6-methyl-
6H-indolo[2,3- b]quinoline (87) was the most cytotoxic with
a mean GI50 value of 0.78 lM and also exhibited selective
cytotoxicities for HL-60 (TB), K-562, MOLT-4, RPMI-8226
and SR with GI50 values of 0.11, 0.42, 0.09, 0.14, and
0.19 l lM, respectively (Fig. 38).
The studies were further extended by Long et al. (2005) who
had synthesized various 4-anilinofuro[2,3-b]quinoline and 4-
anilinofuro (3,2-c) quinoline derivatives and evaluated their
cytotoxic activity against various cancerous cell lines.
6.10. Tetrahydroquinoline and tetrahydropyrimidoquinoline
derivatives
Studies clearly revealed that the quinoline and pyrimidine
nucleuses are an important pharmacophore in various antitu-
mor agents (Karthikeyan et al., 2015). Nowadays pyrimidineN
H
CN
O
N
N
CH3
CH3H3C
CN
NH2
Ar
H3C
Ar = (a) (
Cl
88 89 & 90
Figure 39 Structure of novel tetrahydroquinoline (88–90), and te
anticancer activity against both HCT116 and MCF7 cancer cell lines.
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(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009based potent anticancer drugs are available in the market,
for example, gefitinib (IressaTM) (Wakeling et al., 2002) and
erlotinib (TarcevaTM) (Moyer et al., 1997), and thus, it is con-
sidered as an attractive target for the design of new anticancer
agents. Recently, several tetrahydroquinolines and their
pyrimidine derivatives were synthesized and evaluated for their
anticancer activity, and a number of tetrahydropyrimido-
quinolines derivatives were reported for their anticancer activ-
ity (Faidallah and Rostomb, 2013; Alqasoumi et al., 2010).
Taking into consideration the above findings, and in an
effort to identify novel potent anticancer leads through the
combination of the two active anticancer moieties, Gedawy
et al. (2015) prepared and reported several tetrahydroquinoli-
nes with different groups at C-2 and C-4 positions. Several tet
rahydropyrimidoquinolin-4-amines and tetrahydropyrimido
quinoline-2,4-diamines with different aryl groups at position
number 5 to substantiate were also reported and also marked
their anticancer activity against both human colon carcinoma
(HCT116) and human breast adenocarcinoma (MCF7) cell
lines.
The results of in vitro anticancer activity showed that seven
compounds 2-Oxo-4-(pyridin-2-yl)-1,2,5,6,7,8-hexahydroquino
line-3-carbonitrile (88); 2-Amino-4-(4-chlorophenyl)-8-isopro
pyl-5-methyl-5,6,7,8- tetrahydro-quinoline-3-carbonitrile (89);
2-Amino-4-(4-fluorophenyl)-8-isopropyl-5-methyl-5,6,7,8- tet-
rahydro-quinoline-3-carbonitrile (90); 5-(4-Chlorophenyl)-9-is
opropyl-6-methyl-6,7,8,9-tetrahydropyrimido-[4,5-b]quinolin-
4-amine (91); 5-(4-Fluorophenyl)-9-isopropyl-6-methyl-6,7,8,9-
tetrahydropyrimido-[4,5-b]quinolin-4-amine (92); 5-(4-Chloro
phenyl)-9-isopropyl-6-methyl-6,7,8,9-tetrahydropyrimido-[4,
5-b]quinoline-2,4-diamine (93) and 5-(4-Fluorophenyl)-9-iso
propyl-6-methyl-6,7,8,9-tetrahydropyrimido-[4,5-b]quinoline-
2,4-diamine (94) possessed potent anticancer activity against
both HCT-116 (colon) and MCF7 (breast) cell lines with IC50
between 16.33 and 34.28 lM (Fig. 39). All these compounds
were also reported more potent than imatinib (IC50 = 34.40
lM) and tamoxifen (IC50 = 34.30 lM). Out of these seven com-
pounds, compound (94) was the most active against HCT-116
cell line with 2.1-fold more potent antitumor activity than ima-N N
N
CH3
CH3
Ar NH2
N N
N
CH3
CH3H3C
Ar NH2
NH2
b)
F
91 & 92 93 & 94
trahydropyrimidoquinoline derivatives (91–94) possesses potent
velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 40 Structure of N- (4-acetyl-4,5-dihydro - 5- (7,8,9- substituted - tetrazolo [1,5-a] - quinolin-4-yl) - 1,3,4-thiadiazol -2- yl)
acetamide derivatives (95 and 96) with halogen substituent at 7th position showing potent cytotoxicity against HeLa cancer cell line.
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Figure 41 Structure of pyrimidoquinoline derivatives (97)
showing remarkable anticancer activity against Ehrlich Ascites
Carcinoma (EAC) cells.
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anticancer activity against the MCF7 cell line, having 2–1.79-
fold more potent anticancer activity than tamoxifen.
On the basis of in vitro outcomes the researchers conclude
that the anticancer activity of the synthesized quinoline and
pyrimidoquinoline compounds appeared to be related to the
cycloalkyl moiety fused to the pyridine ring, since the best
activity was obtained by compounds bearing the branched
cyclohexyl moiety (Compounds 91, 92, 93 and 94).
It was clear that the substituents in quinoline derivatives, at
position 2 had a marked effect on the anticancer activity, since
the compounds with carbonyl or amino groups possessed
potent anticancer activity, while those with the chloro group
at C-2 position were inactive. Thus, it was concluded that
the tetrahydroquinolines and their fused pyrimidine deriva-
tives represented a novel and promising class of anticancer
agents, so researcher proposed further studies to explore the
mechanism of action and to optimize the anticancer activity
of these derivatives.
6.11. 1,3,4-Thiadiazol, tetrazole and quinoline derivatives
1,3,4-Thiadiazol, tetrazole and quinoline derivatives have been
reported as promising candidates for anticancer activity. Num-
ber of articles have been published for thiadiazol, tetrazole and
quinoline containing compounds possessed anticancer activity.
Understanding these facts Sheetal et al. (2012) reported N-[4-
acetyl-5-(6, 7, 8-substituted-2-chloroquinolin-3-yl)- 4,5-dihy
dro-1,3,4-thiadiazol-2-yl]-acetamides compound possessed
anticancer and anti-tubercular activity. The researchers
extended their study and introduced a new heterocyclic com-
pound had tetrazole moiety with quinoline derivatized with
1,3,4- thiadiazolidine ring. The synthesized N- (4-acetyl-4,5-
dihydro - 5- (7,8,9- substituted - tetrazolo [1,5-a] - quinolin-
4-yl) - 1,3,4-thiadiazol -2- yl) acetamides compounds were
screened for their in vitro cytotoxic activity against two cell
lines viz., human breast cancer cell line MCF7 and human cer-
vix cancer cell line HeLa. The GI50, LC50 and TGI values were
evaluated. The DNA cleavage study was also reported. Com-
pounds (95 and 96) with halogen substituent at 7th position
of the target molecules showed potent cytotoxicity against
human cervix cancer cell line HeLa (Fig. 40). DNA cleavage
studies revealed that most of these compounds showedPlease cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009partial cleavage and few of them showed complete cleavage
of DNA.
6.12. Pyrimidoquinoline derivatives
Al-Said et al. (2011) reported in their study synthesis and
investigation of the antiproliferative activity of new quinoline
and pyrimidoquinoline derivatives containing a free sulfon-
amide moiety. Several compounds had been synthesized which
exhibited significant anticancer activity. Quinoline compounds
(97) having substituted benzamide, free amino group, butana-
mide, showed remarkable anticancer activity against Ehrlich
Ascites Carcinoma (EAC) cells (Fig. 41). Docking of these syn-
thesized compounds in the carbonic anhydrase active site sug-
gested that the synthesized compounds may act as carbonic
anhydrase inhibitors and this may contribute in part to their
anticancer activity.
6.13. Quinoline sulfonamide derivative
Quinoline and sulfonamide derivatives are important biologi-
cally active compounds that possess potent antitumor activity
(Kouznetsov et al., 2006). Acetylation of histones in chromatin
involved in the regulation of gene transcription and is tightlyvelopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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Figure 42 Structure of compound PQ7 (6- methoxy- 8- [(2-
furanylmethyl)amino]- 4-methyl -5- (3 trifluoro-methylphenyloxy)
quinoline, 98) having promising anticancer activity against T47D
breast cancer cells.
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deacetylase (HDAC) activities. HDACs mediate changes in
nucleosome conformation are important in the regulation of
gene expression and also are involved in cell cycle progression
and differentiation. Alterations of HDACs were identified in
tumor cells and contributed to the massive perturbations of
gene expression in numerous tumors. HDAC inhibition leads
to differentiation, cell cycle arrest and apoptosis in tumor cells
(Hsi et al., 2004). Recently new set of sulfonamide derivativesN
N
H
O
NH
CH3
CH3
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N
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Figure 43 Structure of N-2[4 Dimethylamino)ethyl]acridine-4-car
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(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009have been reported as potent histone deacetylases inhibitors
(HDACIs) (Finn et al., 2005; Ghorab et al., 2007).
6.14. 6-Methoxy- 8- [(2-furanylmethyl)amino]- 4-methyl -5- (3
trifluoro-methylphenyloxy) quinoline derivatives
Cancer cells have a tendency to reduce capacity of gap junction
inter-cellular communication (GJIC). The enhancement of
GJIC induced apoptosis, decreased cell viability, and attenu-
ated tumor growth.
Heiniger et al. (2010) reported a second generation of PQ
analogues [PQ7 i.e. 6- methoxy- 8- [(2-furanylmethyl)amino]-
4-methyl -5- (3 trifluoro-methylphenyloxy) quinoline, 99] and
examined its activates GJIC activity mediated tumor growth
inhibitory activity in xenograft T47D mice (Fig. 42). Scrape
load/dye transfer and colony growth assays were performed
to measure GJIC and tumor formation of T47D breast cancer
cells. Results showed that PQ7 (98) at 500 nM induced a 16-
fold increased in the GJIC in T47D cells, and 50% decreased
of colony growth with 100 nM concentration. PQ7-treated
nu/nu mice showed a 100% regression of xenograft tumor
growth of T47D cells. The authors concluded that the
second-generation PQ7 (98) had a promising role in exerting
anti-tumor activity in human breast cancer cells.
6.15. N-2[4 Dimethylamino)ethyl]acridine-4-carboxamide
derivatives
Acridine-4-carboxamides have been reported as a new genera-
tion of intercalators which are active against solid tumors and
leukemia. A number of studies have been reported for their
capacity to bind to DNA, for their DNA-damaging activityN
N
H
O
H2
N
OH
DACAH (100)
N
H
N
H
O
H2
N
OH
amino-DACAH (102)
NH2
boxamide derivatives (99–102) having DNA cleavage property.
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Figure 44 Structure of compounds bosutinib (103), lenvatinib (104), cabozantinib (105) and tipifarnib (106) quinoline nucleus under
clinical trial.
Review on developments of quinoline-based anticancer agents 25in whole cells and isolated nuclei, and for their inhibitory effect
on RNA synthesis in a cell-free system (Atwell et al., 1987;
Denny et al., 1990). A model of the acridine-4-carboxamide-
DNA complexes were proposed by Wakelin and Denny
(1990), suggesting intercalation of acridine ring between base
pairs with the 4-carboxamide moiety located in the minor
groove. The proposed structure of the substituent at position
4 seems to be the important factor in the stabilization of the
drug-DNA complex as well as in the GC specificity of these
acridines (Bailly et al., 1992). An antitumor drug N-[2-(dime
thylamino)ethyl]acridine-4-carboxamide (DACA, 99) a
acridine-4-carboxamide congener and its three close structural
analogues N-[2-(hydroxyethylamino)ethyl]acridine-4-carboxa
mide (DACAH, 100), N-[2-(dimethylamino) ethyl]-9-aminoa
cridine-4-carboxamide (amino-DACA, 101), and N-[2-(hydro
xyethylamino)ethyl]-9-aminoacridine- 4-carboxamide (amino-
DACAH, 102) were further studied by the same research
group to determine their ability to inhibit RNA synthesis
in vitro and to form topoisomerase II-mediated DNA lesions
in relation to cell-killing activity (Fig. 43). Results showed that
the stabilization of the cleavable complex of topoisomerase II
with DNA by acridine-4-carboxamides is not as important for
the cytotoxic action of these compounds, but the compounds
which can penetrate cell membrane easily and are able to form
a strong intercalative complex with DNA, for example amino-
DACA, may enhance DNA cleavage by topoisomerase II. The
enhancement of DNA cleavage occurs only when used at low
doses while at higher concentrations they act as catalytic inhi-
bitors. The results also suggested that the compound having 4-
carboxamide chain attached with N-2-(dimethylamino)ethyl
moiety resulted in more efficient transport through cell mem-
branes, higher cytotoxicity, and DNA-damaging activity. ThusPlease cite this article in press as: Jain, S. et al., Comprehensive review on current de
(2016), http://dx.doi.org/10.1016/j.arabjc.2016.10.009compound amino-DACA, which easily penetrates the cell
membrane, fully inhibited DNA break formation, whereas
other analogues exhibited a lower degree of protection when
used at high concentration.7. Future prospects of quinoline derivatives
Nowadays quinoline nucleus has gained popularity in the
development of new anticancer drugs. Numbers of quinoline
congeners have been synthesized daily and some of them
showed excellent results on various types of cancer cells,
through different mechanisms of action. Recently, three pro-
tein kinase inhibitors (Bosutinib, Lenvatinib, and Cabozan-
tinib) (103–105) and an inhibitor of farnesyltransferase
(Tipifarnib) (106), considered as potential anticancer agents,
entered into phase of clinical trials (Afzal et al., 2014) (Fig. 44).8. Conclusion
Quinoline or 1-aza-naphthalene is a weak tertiary base, composed of
benzene and pyridine ring fused at two adjacent carbon atoms
obtained by condensation of a benzene ring with pyridine. The quino-
line ring plays an important role in biological and pharmacological
activities. In recent years, large numbers of quinoline derivatives,
including mono-, di-, tri-, tetra- and heterocyclic substituents have
been synthesized and their cytotoxic activity reported. These quinoline
and their derivatives possessed remarkable anticancer activity due to
their structure diversity, which are responsible for their anticancer
activities. Till date a large number of quinoline derivatives have been
marketed for their cytotoxic activity and now scientist is also focusing
to introduce new quinoline molecules in market to encompass anti-
cancer activity.velopments of quinoline-based anticancer agents. Arabian Journal of Chemistry
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